| Literature DB >> 28336505 |
Huberta E Hart1,2, Inge Etm Geilen1, Elke de Leeuw1, Guy Ehm Rutten1, Rimke C Vos1.
Abstract
BACKGROUND: Little attention has been paid to self-management support of patients with well-controlled type 2 diabetes mellitus (T2DM). Most studies evaluated the addition of self-management support to regular diabetes care, but self-management as an alternative for part of regular diabetes care has hardly been studied. In this study, we offered patients with well-controlled T2DM the opportunity to perform the 3 quarterly monitoring sessions at home using an Internet-based self-management program, resulting in online personalized advice.Entities:
Keywords: mild cognitive impairment; self-care; telemedicine; type 2 diabetes mellitus
Year: 2017 PMID: 28336505 PMCID: PMC5383800 DOI: 10.2196/resprot.6910
Source DB: PubMed Journal: JMIR Res Protoc ISSN: 1929-0748
Characteristics of all (N=282), eligible (n=154), and ineligible (n=128) patients for Internet-based self-management.
| Characteristics | Patients with well-controlled T2DMa, | Eligible patients, | Ineligible patients, | |
| Total number of patients | 282 (100) | 154 (54.6) | 128 (45.4) | |
| Age in years, mean (SD) | 63.0 (13.5) | 59.3 (12.1) | 67.6 (13.8) | <.001 |
| Sex, female | 122 (43.3) | 58 (37.7) | 64 (50) | .04 |
| Ethnicity, Western Europeanb | 184 (74.5) | 121 (78.6) | 63 (67.7) | .06 |
| Educational level, lowc | 53 (58.2) | 39 (52.7) | 25 (65.8) | .15 |
| Diabetes duration, years, median (IQRd) | 6.6 (7.0) | 5.5 (5.2) | 7.7 (7.5) | .002 |
| HbA1ce (mmol/mol), median (IQRd) | 48.0 (6) | 48.0 (7) | 49.0 (7) | .01 |
| HbA1c (%),median (IQRd) | 6.5 (0.6) | 6.5 (0.6) | 6.6 (0.6) | .01 |
| LDLf cholesterol (mmol/L), median (IQRd) | 1.90 (0.6) | 2.00 (0.7) | 1.90 (0.7) | .15 |
| Systolic blood pressure (mm Hg), median (IQRd) | 128 (15) | 128 (18) | 129 (17) | .06 |
| BMIg (kg/m2), median (IQRd) | 28.0 (6.1) | 27.6 (5.8) | 28.7 (6.8) | .33 |
| Microvascular complications | 77 (28.6) | 33 (22.9) | 44 (35.2) | .03 |
| Cardiovascular disease | 66 (23.4) | 29 (18.8) | 37 (28.9) | .05 |
| Lifestyle advice only | 49 (17.4) | 31 (20.1) | 18 (14.1) | .18 |
| Insulin use | 29 (10.3) | 10 (6.5) | 19 (14.8) | .02 |
aT2DM: type 2 diabetes mellitus.
bEthnicity N=247; n=154 in eligible patients and n=93 in ineligible patients.
cEducation N=112; n=74 in eligible patients and n=38 in ineligible patients.
dIQR: interquartile range.
eHbA1c: hemoglobin A1c.
fLDL: low-density lipoprotein.
gBMI: body mass index.
Figure 1Flow chart of the study.
Ineligibility of patients with well-controlled type 2 diabetes for Internet-based self-management; models are adjusted for health center.
| Characteristics | Model 1 | Model 2 (including ethnicity) | ||
| Odds ratio (95% CI) | Odds ratio (95% CI) | |||
| Age in years | 1.05 (1.03-1.08) | <.01 | 1.06 (1.03-1.09) | <.001 |
| Sex, female | 1.55 (0.90-2.67) | .11 | 1.27 (0.68-2.38) | .45 |
| Diabetes duration in years | 1.07 (0.78-1.47) | .69 | 1.56 (1.04-2.34) | .03 |
| Microvascular complications (present) | 1.14 (0.62-2.11) | .68 | 0.94 (0.46-1.94) | .87 |
| Cardiovascular disease (present) | 1.19 (0.61-2.31) | .61 | 1.41 (0.67-3.00) | .37 |
| Insulin use (present) | 1.65 (0.63-4.30) | .31 | 1.63 (0.66-4.79) | .37 |
| Lifestyle advice only (present) | 0.61 (0.29-1.28) | .19 | 0.56 (0.23-1.36) | .20 |
| Body mass index (index scores) | 1.04 (0.98-1.11) | .16 | 1.05 (0.98-1.12) | .15 |
| Ethnicity (non–Western European) | - | - | 3.64 (1.67-7.92) | .001 |
Characteristics of patients invited for Internet-based self-management.
| Characteristics | Total population, | Participating patients, | Nonparticipating patients, | |
| Total number of patients | 154 (100) | 57 (37) | 97 (63) | |
| Age in years, mean (SD) | 59.3 (12.1) | 55.2 (10) | 61.7 (13) | .001 |
| Sex, male | 96 (62.3) | 40 (70) | 56 (58) | .12 |
| Ethnicity (Western European) | 121 (78.6) | 47 (83) | 74 (76) | .37 |
| Educational level, low (n=74) | 39 (52.7) | 15 (50) | 24 (55) | .04 |
| Diabetes duration, years, median (IQRa) | 5.5 (5.2) | 4.7 (6) | 5.7 (6) | .05 |
| HbA1cb (mmol/mol), median (IQRa) | 48.0 (7) | 47.0 (8) | 48.0 (6) | .13 |
| HbA1c (%),median (IQRa) | 6.5 (0.6) | 6.5 (1) | 6.5 (1) | .13 |
| LDLc cholesterol (mmol/L), median (IQRa) | 2.0 (0.7) | 2.0 (1) | 2.0 (1) | .95 |
| Systolic blood pressure (mm Hg), median (IQRa) | 128 (18) | 122 (18) | 128 (15) | .06 |
| BMId (kg/m2), median (IQRa) | 27.6 (5.8) | 27.0 (5) | 28.5 (6) | .07 |
| Microvascular complications | 33 (22.9) | 8 (28) | 25 (15) | .09 |
| Cardiovascular disease | 29 (18.8) | 10 (18) | 19 (20) | .75 |
| Lifestyle advice only | 31 (20.1) | 10 (18) | 21 (22) | .54 |
| Oral diabetes medication use | 121 (78.6) | 47 (83) | 74 (76) | .37 |
| Statin use | 115 (74.7) | 38 (67) | 77 (79) | .08 |
| Insulin use | 10 (6.5) | 4 (7.0) | 6 (6) | .84 |
aIQR: interquartile range.
bHbA1c: hemoglobin A1c.
cLDL: low-density lipoprotein.
dBMI: body mass index.
Quality of life, illness perceptions, and treatment satisfaction.
| Questionnaires | Participating patients | Nonparticipating patients | |
| Number of questionnaires returned, n (%) | 45 (79) | 21 (22) | |
| EQ-5D health state utility score, median (IQRa) | 1.0 (0.16) | 0.89 (0.19) | .20 |
| EQ VASb (range 0-100), mean (SD) | 75.9 (11.5) | 77.2 (13.7) | .68 |
| BIPQc consequences (range 0-10) median (IQRa) | 3.0 (5) | 1.0 (5) | .27 |
| BIPQ timeline (range 0-10), median (IQRa) | 10.0 (2) | 8.0 (4) | .03 |
| BIPQ personal control (range 0-10), median (IQRa) | 8.0 (1) | 6.0 (4) | .21 |
| BIPQ treatment control (range 0-10), median (IQRa) | 8.0 (2) | 8.0 (2) | .06 |
| BIPQ identity(range 0-10), median (IQRa) | 2.0 (3) | 2.0 (4) | .58 |
| BIPQ concern (range 0-10), median (IQRa) | 4.0 (5) | 2.0 (7) | .89 |
| BIPQ understanding (range 0-10), median (IQRa) | 8.0 (2) | 7.0 (3) | .16 |
| BIPQ emotional response (range 0-10), median (IQRa) | 2.0 (4) | 1.0 (3) | .33 |
| DTSQd total score (range 0-48), median (IQRa) | 40.0 (6) | 44.0 (10) | .05 |
aIQR: interquartile range.
bEQ VAS: EQ visual analogue scale.
cBIPQ: Brief Illness Perception Questionnaire.
dDTSQ: Diabetes Treatment Satisfaction Questionnaire.